Method for alleviating asthenopia and liquid composition for ophthalmic use

Abstract

The present invention relates to a method for alleviating asthenopia and a liquid composition for ophthalmic use. Specifically, on one hand, the invention relates to a liquid composition for eyes. The invention relates to a skin-care lotion, which is prepared from the following components: glycerol, p-hydroxyacetophenone, sodium hyaluronate, propylene glycol, menthol, borneol, methyl diisopropyl propionamide, menthol, SOLUBILISANT LRI, edetate disodium, water-locking magnetite, radix gentianae extract, totarol, sodium citrate, ectodoine, ergothioneine, hydrolyzed red algae extract and water. Furthermore, the invention also relates to an application of the liquid composition in preparation of a product for relieving eye asthenopia for eye use. The liquid composition of the present invention exhibits excellent properties, for example as described in the specification.

Description

TECHNICAL FIELD

[0001] The present invention belongs to the field of medicine and relates to a method for alleviating eye strain, and to a liquid composition for ophthalmic use made for this method for alleviating eye strain. The liquid composition for ophthalmic use of the present invention exhibits excellent properties. BACKGROUND

[0002] The eye is the organ of vision in humans, which consists of the eyeball and its accessory structures. The eyeball is the main part of the visual organ, which has two functions of light refraction imaging and photosensitive transduction. The accessory parts of the eye, such as eyelids, conjunctiva, lacrimal apparatus, eye muscles, and intraorbital fascia and fat, have the functions of protection, movement, and support for the eyeball. The perfection of the structures of the eye is of great significance for the eye to complete the visual function.

[0003] The normal function of the eye plays an important role in people's high-quality life. However, with the popularity of electronic products, people spend more and more time using their eyes on electronic screens such as mobile phones and computers, especially today with the development of mobile networks. In the information age, people's eye time has increased several times more than in the past few decades, and they increasingly rely on video display terminals such as computers and televisions for various activities. In recent years, the number of people suffering from eye strain in China has increased exponentially, and according to relevant statistics, there are now as many as 150 million people. However, people's vision care concepts have not kept pace. Eye strain is a common disease in ophthalmology, a kind of visual fatigue syndrome caused by various reasons. Its clinical manifestations are diverse, and it often occurs after a long time of close eye use or shortly after eye use, with a transient visual function decline or a series of eye discomfort. Mild symptoms include eye swelling, dryness, photophobia, burning, redness, periorbital pain, nasal root and forehead swelling, and blurred vision. Severe symptoms can include eye swelling, severe headache or migraine, cold sweat, pale complexion, slow heart rate, or tightness in the precordial region, and some people may also experience symptoms such as inability to concentrate, listlessness, fear of reading, insomnia, and memory loss. If not treated in time, it can cause visual impairment and eventually lead to myopia, excessive psychological stress, attention to stereoscopic concentration, and neurasthenia. The main causes of formation are four: overuse of the eye, improper use of the eye, disease, and accommodative visual fatigue. After frequent occurrence of eye strain, continued use of electronic screens can cause the eye to become more and more dry and more and more prone to dryness.

[0004] A common consequence of long-term use of the eye on electronic screens is dry eye syndrome, and the number of people with dry eye syndrome in China today is as high as 360 million, especially among white-collar workers, 80% of whom have eye strain problems. These alarming figures will result in a huge burden on ophthalmic medical care, and it is of great significance to prevent and intervene before the development of eye disease has a deep impact on life.

[0005] The existing method for relieving eye fatigue is mainly to drop eye drops into the eyes. Although this method is effective, it will increase the burden of the eyeball, and because the conventional eye drops are added with preservatives, it may cause additional damage to the eyeball.

[0006] However, it has very positive technical significance to solve eye visual fatigue by external use of drugs without entering the eyes, especially the drugs do not touch the internal eye structure and can avoid adverse side effects. SUMMARY

[0007] The purpose of the present application is to provide a method for relieving eye visual fatigue, especially to provide a method for relieving eye visual fatigue by using eye protection liquid outside and around the eyes. Another purpose of the present application is to provide a liquid composition for the eye used in the above-mentioned method for relieving eye visual fatigue, which can be called eye protection liquid or eye protection serum.

[0008] To this end, the first aspect of the present application provides a liquid composition for eye use, which comprises the following components in the following weight proportions: glycerin 5.4g~6.6g, p-hydroxyacetophenone 0.27g ~0.33g, sodium hyaluronate 0.045g~0.055g, propylene glycol 5.4g ~6.6g, menthyl glycol 0.018g~0.022g, ice 0.018g ~0.022g, methyl diisopropyl propionamide 0.27g~0.33g, menthol 0.018g ~0.022g, SOLUBILISANT LRI 0.225g ~0.275g, disodium edetate 0.027g~0.033g, lock water magnetite 0.45g ~0.55g, gentian root extract 0.18g~0.22g, maotangol 0.045g ~0.055g, sodium citrate 0.0106g~0.013g, ekdoin 0.009g ~0.011g, ergothioneine 0.0045g~0.0055g, hydrolyzed red algae extract 0.0045g ~0.0055g, water q.s. 100g.

[0009] The liquid composition for ophthalmic use according to the first aspect of the present application is prepared using a method comprising the following steps: 1) Dissolve half of the prescribed amount of glycerin and p-hydroxyacetophenone in a water bath to make a pre-prepared solution A, ready for use; 2) Pre-disperse sodium hyaluronate, 10 times its weight of water, and the remaining amount of glycerin to make a pre-prepared solution B, ready for use; 3) Stir propylene glycol, menthyl glycol and borneol to homogeneity, heat to 60-70°C to dissolve the material, then cool to room temperature, add methyl diisopropyl propionamide and menthol, stir to dissolve, then add SOLUBILISANT LRI, stir to homogeneity, to make a pre-prepared solution C; 4) Place the appropriate amount of water (for example, about 60% of the prescribed amount) and disodium edetate in a solution kettle, stir to dissolve, then add the pre-prepared solution B while stirring, then heat to 85°C while stirring, continue to maintain the temperature and stir for 30 minutes, cool to 40°C, then add the pre-prepared solution A while stirring, stir to homogeneity; 5) Add the pre-prepared solution C, water-retaining magnetite, gentian root extract, prunol, sodium citrate, ectoine, ergothioneine, hydrolyzed red algae extract, and the remaining amount of water to the solution obtained in the previous step in sequence, stir to dissolve at a temperature of 40-45°C, filter through 0.8 µm and 0.45 µm microporous filters in sequence, and then dispense, to obtain the final product; for example, the liquid composition further comprises threonine and / or sodium bisulfite; for example, it further comprises threonine 0.18-0.22 g and / or sodium bisulfite 0.0675-0.0825 g; for example, the threonine and / or sodium bisulfite are added together with the ectoine.

[0010] The liquid composition for ophthalmic use according to the first aspect of the present application comprises the following components in the following proportions by weight: glycerin 6 g, p-hydroxyacetophenone 0.3 g, sodium hyaluronate 0.05 g, propylene glycol 6 g, menthyl glycol 0.02 g, borneol 0.02 g, methyl diisopropyl propionamide 0.3 g, menthol 0.02 g, SOLUBILISANT LRI 0.25 g, disodium edetate 0.03 g, water-retaining magnetite 0.5 g, gentian root extract 0.2 g, prunol 0.05 g, sodium citrate 0.0118 g, ectoine 0.01 g, Threonine 0.2 g, Sodium bisulfite 0.075 g, Ergothioneine 0.005 g, Hydrolyzed red algae extract 0.005 g, Water q.s. to 100 g.

[0011] Liquid composition for ophthalmic use according to the first aspect of the application, comprising the following proportions by weight of ingredients: Glycerol 5.4 g, p-Hydroxyacetophenone 0.33 g, Sodium hyaluronate 0.045 g, Propylene glycol 6.6 g, Menthol 0.018 g, Borneol 0.022 g, Methyl diisopropylpropionamide 0.27 g, Menthol 0.022 g, SOLUBILISANT LRI 0.275 g, Disodium edetate 0.027 g, Gallium 0.55 g, Gentian root extract 0.18 g, Peach alkanoids 0.055 g, Sodium citrate 0.0106 g, Ecdyson 0.011 g, Threonine 0.18 g, Sodium bisulfite 0.0825 g, Ergothioneine 0.0045 g, Hydrolyzed red algae extract 0.0055 g, Water q.s. to 100 g.

[0012] Liquid composition for ophthalmic use according to the first aspect of the application, comprising the following proportions by weight of ingredients: Glycerol 6.6 g, p-Hydroxyacetophenone 0.27 g, Sodium hyaluronate 0.055 g, Propylene glycol 5.4 g, Menthol 0.022 g, Borneol 0.018 g, Methyl diisopropylpropionamide 0.33 g, Menthol 0.018 g, SOLUBILISANT LRI 0.225 g, Disodium edetate 0.033 g, Gallium 0.45 g, Gentian root extract 0.22g Peach tannin 0.045g Sodium citrate 0.013g Ectocin 0.009g Threonine 0.22g Sodium bisulfite 0.0675g Ergothioneine 0.0055g Hydrolyzed red algae extract 0.0045g Add water to a volume of 100g.

[0013] Furthermore, a second aspect of the present invention provides the use of a liquid composition in the preparation of a product for use in relieving eye strain, said liquid composition comprising the following components in weight proportions: Glycerin 5.4g~6.6g p-Hydroxyacetophenone 0.27g ~ 0.33g Sodium hyaluronate 0.045g~0.055g Propylene glycol 5.4g ~ 6.6g Mongan glycol 0.018g~0.022g Borneol 0.018g ~ 0.022g Methyl diisopropyl propionamide 0.27g~0.33g Menthol 0.018g ~ 0.022g The solubilities of sodium lactate (LRI) are 0.225g to 0.275g. Disodium edetate 0.027g~0.033g Water-locking magnet 0.45g ~ 0.55g Gentian root extract 0.18g~0.22g Peach tannin 0.045g ~ 0.055g Sodium citrate 0.0106g~0.013g Ectocin 0.009g ~ 0.011g Ergothioneine 0.0045g~0.0055g Hydrolyzed red algae extract 0.0045g ~ 0.0055g Add water to a volume of 100g.

[0014] According to a second aspect of the invention, the liquid composition is prepared using a method comprising the steps of: 1) Dissolve half the amount of glycerin and p-hydroxyacetophenone in a water bath until completely dissolved, and use this as pre-prepared solution A for later use; 2) Pre-disperse sodium hyaluronate, 10 times its weight of water, the remainder glycerol, as pre-preparation B, ready for use; 3) Stir propylene glycol, menthyl glycol and borneol until homogeneous, heat to 60-70°C to dissolve the material, then cool to room temperature, add methyl diisopropyl propionamide and menthol, stir until dissolved, then add SOLUBILISANT LRI, stir until homogeneous, as pre-preparation C; 4) Place an appropriate amount of water (for example about 60% of the prescription amount) and disodium edetate in a preparation kettle, stir until dissolved, add pre-preparation B with stirring, then heat to 85°C with stirring, continue to maintain the temperature for 30 minutes, cool to 40°C, add pre-preparation A with stirring, stir until homogeneous; 5) Add pre-preparation C, magnetite, gentian root extract, peonidin, sodium citrate, ectoine, ergothioneine, hydrolysed red algae extract, the remainder of the water, to the liquid obtained in the previous step, stir until dissolved at a temperature of 40-45°C, filter through 0.8 µm and 0.45 µm microporous filters in that order, dispense, and it is ready; for example, the liquid composition also includes threonine and / or sodium bisulfite; for example, it also includes threonine 0.18g-0.22g and / or sodium bisulfite 0.0675g-0.0825g; for example, the threonine and / or sodium bisulfite are added together with the ectoine.

[0015] Use according to the second aspect of the application, in which the liquid composition comprises the following components in the following proportions by weight: glycerol 6g, p-hydroxyacetophenone 0.3g, sodium hyaluronate 0.05g, propylene glycol 6g, menthyl glycol 0.02g, borneol 0.02g, methyl diisopropyl propionamide 0.3g, menthol 0.02g, SOLUBILISANT LRI 0.25g, disodium edetate 0.03g, magnetite 0.5g, gentian root extract 0.2g, peonidin 0.05g, sodium citrate 0.0118g, ectoine 0.01g, threonine 0.2g, sodium bisulfite 0.075g, ergothioneine 0.005g, hydrolysed red algae extract 0.005g, Water q.s. to 100 g.

[0016] Use according to the second aspect of the application, wherein the liquid composition comprises the following proportions by weight of ingredients: Glycerol 5.4 g, p-Hydroxyacetophenone 0.33 g, Sodium hyaluronate 0.045 g, Propylene glycol 6.6 g, Menthyl isovalerate 0.018 g, Borneol 0.022 g, Methyl diisopropylpropionamide 0.27 g, Menthol 0.022 g, SOLUBILISANT LRI 0.275 g, Disodium edetate 0.027 g, Gallium 0.55 g, Gentian root extract 0.18 g, Paeonol 0.055 g, Sodium citrate 0.0106 g, Ecdyson 0.011 g, Threonine 0.18 g, Sodium bisulfite 0.0825 g, Ergothioneine 0.0045 g, Hydrolyzed red algae extract 0.0055 g, Water q.s. to 100 g.

[0017] Use according to the second aspect of the application, wherein the liquid composition comprises the following proportions by weight of ingredients: Glycerol 6.6 g, p-Hydroxyacetophenone 0.27 g, Sodium hyaluronate 0.055 g, Propylene glycol 5.4 g, Menthyl isovalerate 0.022 g, Borneol 0.018 g, Methyl diisopropylpropionamide 0.33 g, Menthol 0.018 g, SOLUBILISANT LRI 0.225 g, Disodium edetate 0.033 g, Gallium 0.45 g, Gentian root extract 0.22 g, Paeonol 0.045 g, Sodium citrate 0.013 g, Ecdyson 0.009 g, Threonine 0.22 g, Sodium bisulfite 0.0675 g, Ergothioneine 0.0055 g, Hydrolyzed red algae extract 0.0045 g, Water q.s. 100 g.

[0018] In describing method steps in this application, although the recited specific steps in sequence might vary from other implementations that are described elsewhere herein, it is believed that one skilled in the art would fully appreciate the method steps and sequences in light of the detailed disclosure provided herein. Any of the embodiments of any of the aspects of the application can be combined with any of the other embodiments of the aspects, as long as they are not mutually exclusive. In addition, any of the technical features in any of the embodiments of any of the aspects of the application can be applicable to the technical features in other embodiments, as long as they are not mutually exclusive.

[0019] The application is further described below.

[0020] All documents cited in the present application, in their entirety, are incorporated by reference into the present application and, in the event of any inconsistency between the disclosure of the present application and the documents, the disclosure of the present application is controlling. Furthermore, various terminology and phrases used in the present application have the general meanings ascribed to them by those skilled in the art, even though the present application wishes to provide more detailed descriptions and explanations of these terms and phrases, and in the event of any inconsistency between the meanings of these terms and phrases as commonly understood and the meanings ascribed to them in the present application, the meanings ascribed to them in the present application are controlling.

[0021] The various raw materials described above in the present application are readily available from commercial sources.

[0022] In the present application, propylene glycol, as used unless otherwise specified, is 1,3-propanediol.

[0023] In the present application, the occlusif used is Pentavitin®, available from DSM Nutritional Products, which is a moisturizing factor for cosmetic use. The occlusif is a sugar isomer, which is very similar in composition to the natural sugar complex found in the stratum corneum, and thus it has good skin affinity, and can bind to keratin as an occlusif, hence the name "occlusif". The occlusif is derived from edible corn sugar (plant-based D-glucose), and is a sugar complex similar in structure to the carbohydrate complex found in human skin stratum corneum (NMF natural moisturizing factor). It can bind to the epsilon-amino group of lysine in the keratin of the keratinocytes, and this unique binding mechanism makes it difficult to be washed away as a moisturizing active ingredient, and it can continuously improve the hydration of the skin until the keratinocytes naturally age and fall off.

[0024] In the present application, the methyl diisopropyl propanamide used is purchased from Guangzhou Zhongkang Pharmaceutical Technology Co., Ltd., with the trade name: WS-23, and the raw material reporting code for cosmetic coolants is: 003301-00435-1138. Methyl diisopropyl propanamide, also known as N,2,3-trimethyl-2-isopropyl butanamide, is a high-quality cooling agent with high cooling activity and no side effects such as burning, numbness and irritation, and is mainly used as a cooling agent in candies, oral care, medicine, etc. N,2,3-trimethyl-2-isopropyl butanamide has very strong cooling effect and long-lasting cooling effect. The product is mainly used as a cooling agent in medicine, oral care products, food, beverages, tobacco, cosmetics and candies. When used with fragrances, it has good compatibility and synergy, and the effect of increasing fragrance is significant. It provides a better raw material selection for new cooling products in the food, daily chemical, pharmaceutical and other industries.

[0025] In the present application, the p-hydroxyacetophenone used is purchased from Beijing Tianhong Tianda Co., Ltd., and is UKfinecare®HP, also known as 4-hydroxyacetophenone. It is widely used in the fields of medicine, perfume, cosmetics, etc., and cosmetics are its main application field. P-hydroxyacetophenone has a preservative effect. Compared with traditional cosmetic preservatives, p-hydroxyacetophenone has no carcinogenicity and no irritation, and has the advantages of stronger antibacterial and preservative properties, higher safety, etc. It has been widely used in high-end cosmetics.

[0026] In the present application, the SOLUBILISANT LRI used is purchased from Sensient Cosmetic Technologies Co., Ltd. in France, and the cosmetic raw material reporting code is: 117573-01033-4456. The main chemical components are PPG-26-butyl alcohol polyether-26 and PEG-40 hydrogenated castor oil. SOLUBILISANT LRI is a unique surfactant mixture with super strong solubilizing effect, which can solubilize fragrances, essential oils, vitamins and other cosmetic oily ingredients into water to form a stable microemulsion system. SOLUBILISANT LRI has strong solubilizing ability, so its dosage in the formula is much smaller than that of other similar products. It has high safety and no irritation to the skin and eyes. The solubilizing ability of SOLUBILISANT LRI is stronger for more complex (mixed) hydrophobic mixtures, which can leave a soft and smooth feeling on the skin surface without stickiness, and can also show the fragrance of the fragrance.

[0027] In the present application, the gentian root extract used is a cosmetic raw material with the trade name of 2.5 generation Gentiana Anti-irritating Factor® from Shanghai Gaiyu Biological Technology Co., Ltd., product number: JY1004-2.5. The 2.5 generation Gentiana Anti-irritating Factor® uses the genuine medicinal plant gentian, adopts a unique separation and extraction technology, has anti-irritating and anti-inflammatory effects, is a mainstream anti-allergic and anti-irritating raw material on the market, and has good anti-allergic and irritation-reducing effects when added with 0.5%. It is a natural plant gentian root extract that can completely replace chemical hormones and has anti-inflammatory, itching-relieving, redness-removing, and swelling-reducing effects.

[0028] In the present invention, the sodium hyaluronate used is readily available from commercial sources, which is sodium hyaluronate with a molecular weight of 1.2 million. Sodium hyaluronate is the sodium salt form of hyaluronic acid, also known as sodium glass acid, with the chemical formula (C14H20NO11Na)n, which is a glucuronan, a natural polysaccharide widely present in human connective tissue, skin, eyes and joint fluid. It has excellent moisturizing, anti-aging, repairing and lubricating functions, so it is widely used in beauty, medicine and health care. The molecular structure of sodium hyaluronate is formed by alternating arrangement of glucuronic acid and N-acetylglucosamine, which has strong water absorption capacity, each molecule can absorb hundreds of times of water, so it has significant effect on maintaining skin hydration and improving skin elasticity. In beauty and skin care, sodium hyaluronate is often used in moisturizing products such as cream, serum and mask, to help relieve dryness, tightness and fine lines, and keep skin smooth and moist. In addition, sodium hyaluronate is also widely used in joint treatment (such as arthritis injection), ophthalmology (such as artificial tears) and wound repair, to help relieve joint pain, speed up wound healing and relieve eye dryness and other problems. Due to its high safety and naturalness, sodium hyaluronate has become an indispensable important ingredient in modern medicine and skin care products. Hyaluronic acid (HA) is a linear macromolecular polysaccharide, which is composed of D-glucuronic acid and N-acetylglucosamine connected by β-1,3 and β-1,4 glycosidic bonds. Its chemical structure makes it have strong hydrophilicity. There are a large number of hydrophilic groups such as carboxyl and hydroxyl groups on the molecular chain, which can form hydrogen bonds with water molecules, so that sodium hyaluronate has good water retention performance. Sodium hyaluronate is a biodegradable substance. In the body, it can be degraded by hyaluronidase. Hyaluronidase is an enzyme present in many tissues of the human body, which can hydrolyze the glycosidic bond of sodium hyaluronate. This degradation property makes sodium hyaluronate have great advantages in medical applications. When sodium hyaluronate is used as a tissue engineering scaffold, it can be gradually degraded as the tissue repairs and grows, providing space for the formation of new tissue, and its degradation products are some small molecular sugars and other substances, which can be metabolized and absorbed by the human body without adverse effects on the human body.

[0029] In the present application, the used pomegranate rind phenol is also known as Totarol, Rosmarol, CAS No. 511-15-9, purchased from Huari Bao (Guangzhou) Biotechnology Co., Ltd., with a chromatographic purity of more than 98%. Pomegranate rind phenol has very good antibacterial and cleaning effects on human skin, body and oral cavity, and has no irritation and allergic reaction to human skin. Pomegranate rind phenol has been widely proven to have high biological activity, human safety and product formula compatibility, and is applied to clinical medical and cosmeceutical products. The use of rosmarinol is a natural plant extract, which is a highly effective antibacterial agent, and has good antibacterial effect on gram-positive bacteria, including streptococcus, bacillus subtilis, staphylococcus aureus and propionibacterium acnes. Pomegranate rind phenol is a naturally occurring diterpene with strong antibacterial activity, and has very good antibacterial and cleaning effects on human skin, body and oral cavity, and has no irritation and allergic reaction to human skin.

[0030] In the present application, the used edetate disodium is ethylenediaminetetraacetic acid disodium purchased from Nolox Chemicals (Ningbo) Co., Ltd. Dissolvine®NA2, which is a commonly used excellent chelating agent. Ethylenediaminetetraacetic acid disodium is a white or milky white crystalline or granular powder with no odor, no odor or slightly salty. It is odorless, tasteless. It can be dissolved in water and very difficultly dissolved in ethanol. It is an important chelating agent that can chelate metal ions in solution. Prevent discoloration, deterioration, turbidity and oxidative loss of vitamin C caused by metal, and also improve the antioxidant properties of oil (trace metals such as iron and copper in oil promote oil oxidation).

[0031] In the present application, the used menthol is L-MENTHOL purchased from Shanghai Takasago Chemicals Co., Ltd., with the chemical formula C10H20O, which is colorless needle-like crystal with a cooling mint aroma, soluble in ethanol, acetone, diethyl ether, chloroform and benzene and other organic solvents, slightly soluble in water. It is relatively stable in chemical properties and can be volatilized with steam. Menthol is biosynthesized in mint leaves and is a cyclic monoterpene as the main component of mint oil. Mint oil is a highly volatile essential oil produced by plants, and its components are mainly sesquiterpenes, monoterpenes and sesquiterpenes, especially in warm climates. Some important plant pigments are terpenoids or terpenoid-based compounds.

[0032] In the present application, the used menthone glycerol acetal is purchased from Guangdong Dingchun Biological Pharmaceutical Technology Co., Ltd., product code: DC-1102MRC, cosmetic raw material product submission code 004677-00414-575. Menthone glycerol acetal has a variety of important physiological effects in vivo. It can act on biological macromolecules such as proteins, nucleic acids and carbohydrates through various pathways, thereby regulating the physiological processes of the organism. For example, menthone glycerol acetal has antioxidant effects, can scavenge free radicals, and prevent their damage to cells, proteins and DNA. This effect is of great significance for maintaining normal cell function, delaying aging and preventing various diseases. In addition, menthone glycerol acetal can also protect cells from dehydration and freeze-thaw damage by regulating cell osmotic pressure, which is of great significance for the cryopreservation of cells, organisms and tissue engineering materials. Menthone glycerol acetal has good moisturizing effect, can absorb moisture and prevent skin dryness, and has been widely used in cosmetics and personal care products, such as face cream, lotion and shampoo. In addition, menthone glycerol acetal is often used as a preservative in cosmetics to inhibit the growth of bacteria and mold and extend the shelf life of the product. Due to its low toxicity and low allergenicity, menthone glycerol acetal is relatively safe and is widely used in the cosmetics industry. Menthone glycerol acetal is a mixture of cis- and trans-menthone glycerol acetal obtained by extracting eucalyptol from lemon eucalyptus leaves, then hydrogenating eucalyptal to citronellal, and then catalytically condensing citronellal with water. The used menthone glycerol acetal in the present application is determined by gas chromatography area normalization method. The gas chromatography determination conditions are as follows: column oven temperature: 80.0℃, injection temperature: 230.00℃, injection mode: split, flow control mode: pressure, pressure: 101.8kPa, total flow: 44.0mL / min, column flow: 2.00mL / min, linear velocity: 36.8cm / sec, purge flow: 3.0L / min, ion source temperature: 200.00℃, interface temperature: 240.00℃, solvent delay time: 4.00min. The total amount of cis- and trans-isomers of the used menthone glycerol acetal is 98.3%, and a typical chromatogram is shown in Figure 1

[0033] In the present application, the used borneol is natural borneol purchased from Jiangxi Linke Longnail Co., Ltd. It is well known that it is an extract from the branches and leaves of Cinnamomum camphora (L.) Presl, and is also commonly known as camphor tree. Natural borneol is made by extracting and processing fresh branches and leaves of Cinnamomum camphora (L.) Presl, and has the effects of opening the orifices, refreshing the spirit, clearing heat and relieving pain. It is commonly used for treating heat disease coma, convulsions, apoplexy, sudden convulsions, nausea and coma, chest pain, red eyes, mouth sores, sore throat, and ear discharge.

[0034] ​In the present application, the sodium citrate used is purchased from Weifang Yingxuan Industry Co., Ltd., which is also known as trisodium citrate, sodium citrate, and trisodium citrate. It is an organic acid sodium salt. It is white to colorless crystals, has a cool salty taste, and is stable in air. The chemical formula is C6H5Na3O7, it is soluble in water and difficult to dissolve in ethanol. The aqueous solution has a slight alkaline, and is commonly used as a buffering agent, complexing agent, bacterial culture medium, and is used in medicine for diuresis, expectorant, anticoagulant, and is used in food, beverage, electroplating, photography, etc. It is one of the basic reagents for biological tests.

[0035] In the present application, the ectoine used is purchased from Shantou Jiahe Co., Ltd., which is also known as Ectoin, tetrahydro methyl pyrimidine carboxylic acid, 2-methyl-1, 4, 5, 6-tetrahydro pyrimidine-4-carboxylic acid, molecular formula C6H10O2N2. Ectoin was discovered by Professor Galinski in the Egyptian desert in 1985. It is a natural protective component generated by halophilic bacteria in the extracellular layer under the conditions of high temperature, dryness, strong UV radiation, and high salinity, thereby opening the self-repair function. In addition to the desert, the bacteria are also found in saline-alkali land, salt lake, and seawater. Since ectoine is derived from halomonas elongata, it is also called "salt-tolerant bacteria extract". Under the extreme conditions of high salt, high temperature, and high ultraviolet radiation, ectoine protects halophilic bacteria from damage. Studies have shown that ectoine also has good repair and protection effects on the skin, and is one of the biological engineering preparations used in high-end cosmetics.

[0036] In the present application, the ergothioneine used is a product with the trade name SIYOMICRO-ERGO® purchased from Shenzhen Zhongke Xinyang Co., Ltd. Ergothioneine is also known as thiohistidine trimethyl inner salt, ergothioneine, 2-thio-imidazole, EGT, etc., and has the molecular formula C9H15N3O2S. Ergothioneine is a compound discovered in 1909, and was first discovered in a fungus Claviceps purpurea. The pure product is a white crystal, has a solubility of 0.9 mol / L in water at room temperature, and cannot be self-oxidized in a strong alkaline solution at a physiological pH value. Ergothioneine is a natural antioxidant, and can protect cells in the human body. It is an important active substance in the body. Natural antioxidants are safe and non-toxic, and have become a research hotspot. As a natural antioxidant, ergothioneine has entered the field of vision of people. It has many physiological functions, such as scavenging free radicals, detoxification, maintaining DNA biosynthesis, normal cell growth, and cell immunity. Ergothioneine is distributed in some tissues and organs of mammals, and mainly exists in red blood cells. Although no experimental research has shown that animals can synthesize this substance, there must be a way to absorb and retain ergothioneine in animal cells. For carnivorous animals, the ergothioneine in animal tissues can supply the dietary needs. Melville.D.B and Eich.S found that there is ergothioneine in cereal plants. Subsequent studies by Melville.D.B and Genghof.D.S showed that ergothioneine is a common component of many microbial cells, and can be synthesized in several fungi, but cannot be synthesized in bacteria. In edible fungi such as Boletus edulis, Agaricus bisporus, Coprinus comatus, etc., the precursor hercynine required for the synthesis of ergothioneine can be produced. In addition, Coprinus comatus can also produce ergothioneine and other rare amino acids.

[0037] In the present invention, the hydrolyzed red algae extract used is a cosmetic raw material from CODIF INTERNATIONAL company, with the trade name B-SHAPE G, whose main active ingredient is hydrolyzed red algae extract, also containing glycerol and water as adjuvants, cosmetic raw material submission code: 119371-02618-6369. B-SHAPE G is prepared by enzymatic hydrolysis of red algae Polysiphonia brodiei, adding glycerol after clarification, and then filtering and sterilizing. It is well known that hydrolyzed red algae extract has very strong antioxidant effect and is a free radical scavenger. It effectively reduces the invasion of harmful substances and maintains the health of the skin. Hydrolyzed red algae extract mainly contains alginic acid, algal protein, mannitol, essential fatty acids such as linoleic acid and linolenic acid, iodine, as well as 18 kinds of protein amino acids and active polypeptides that have a significant impact on skin physiological processes. In addition, hydrolyzed red algae extract also contains some essential mineral elements for the human body, such as hydrogen, phosphorus, potassium, calcium, magnesium, sulfur, iron, manganese, copper, zinc, etc.

[0038] Threonine was isolated and identified from fibrin hydrolysate by W.C.Rose in 1935. In 1936, Meger studied its spatial structure, and named it threonine due to its similar structure to threose. Threonine has four isomers, and the naturally occurring and physiologically active one is L-threonine. The threonine mentioned in the present invention refers to L-threonine. Threonine is an essential amino acid for the human body, mainly used in medicine, chemical reagents, food fortifiers, feed additives, etc. Threonine is an important nutritional fortifier that can fortify cereals, pastries, dairy products, and has the same effect as tryptophan in relieving human fatigue and promoting growth and development. In medicine, threonine has a water-retaining effect on the human skin due to the hydroxyl group in its structure, and can protect cell membranes by combining with oligosaccharide chains. It can promote phospholipid synthesis and fatty acid oxidation in the body. Its preparation has the medicinal efficacy of promoting human development and resisting fatty liver. Although threonine has many excellent medical uses as described above, its performance of imparting excellent stability to ectoine with sodium bisulfite in the present invention is completely unpredictable in the prior art.

[0039] The present invention uses the above-mentioned materials to prepare a liquid composition for eye use with excellent performance, which can effectively relieve eye visual fatigue. The basic liquid composition prepared by the method of the present invention shows excellent biological effect, and is typically a product approved for marketing by the relevant national regulatory authorities and allowed to be sold with the Guangdong cosmetic network code G 2023423624. Such products are used externally and around the eyes for the relief of human eye fatigue. BRIEF DESCRIPTION OF DRAWINGS

[0040] Figure 1 : Gas chromatogram of monol.

[0041] Figure 2 HPLC chart of solution a after heat treatment.

[0042] Figure 3 HPLC chart of eye care serum of example 1 after heat treatment.

[0043] Figure 4 HPLC chart of eye care serum of example 5 after heat treatment.

[0044] Figure 5 Results of the detection of the relevant items of the liquid composition of example 7 according to the method of the Cosmetics Safety Technical Specifications (2015 edition).

[0045] Figure 6 Results of the detection of the relevant items of the liquid composition of example 6 according to the relevant national standards. DETAILED DESCRIPTION

[0046] The present application can be further described by the following examples, however, the scope of the present application is not limited to the following examples. Those skilled in the art can understand that various changes and modifications can be made to the present application without departing from the spirit and scope of the present application. The present application generally and / or specifically describes the materials used in the experiments and the experimental methods. Although many materials and operating methods used to achieve the purpose of the present application are well known in the art, the present application is described as detailed as possible.

[0047] Example 1: Preparation of a liquid composition for ophthalmic use The present embodiment provides an eye care liquid composition which can be referred to as eye care liquid or eye care serum, the prescription of which is as follows: Glycerin 6g, p-Hydroxyacetophenone 0.3g, Sodium hyaluronate 0.05g, Propylene glycol 6g, Menthol 0.02g, Borneol 0.02g, Methyl diisopropyl propionamide 0.3g, Menthol 0.02g, SOLUBILISANT LRI 0.25g, Disodium edetate 0.03g, Lock water magnetite 0.5g, Gentian root extract 0.2g, Peach genipin 0.05g, Sodium citrate 0.0118g, Ecdyson 0.01g, Ergothioneine 0.005g, hydrolyzed red algae extract 0.005 g, water to 100 g.

[0048] Method of preparation: 1) Half of the prescribed amount of glycerin and p-hydroxyacetophenone are heated in a water bath to complete dissolution, as pre-prepared solution A, ready for use; 2) The sodium hyaluronate, 10 times its weight of water, and the remaining glycerin are pre-dispersed as pre-prepared solution B, ready for use; 3) Propylene glycol, menthyl glycol, and borneol are stirred to homogeneity, heated to 60-70°C to dissolve the materials, then cooled to room temperature, methyl diisopropylpropionamide and menthol are added, stirred to dissolve, then SOLUBILISANT LRI is added, stirred to homogeneity, as pre-prepared solution C; 4) The appropriate amount of water (about 60% of the prescribed amount) is placed in a solution kettle with edetate disodium, stirred to dissolve, pre-prepared solution B is added with stirring, then heated to 85°C with stirring, continues to be stirred for 30 min at 85°C, then cooled to 40°C, pre-prepared solution A is added with stirring, stirred to homogeneity; 5) Pre-prepared solution C, magnetite, gentian root extract, prunol, sodium citrate, ectoine, ergothioneine, hydrolyzed red algae extract, and the remaining water are sequentially added to the liquid obtained in the previous step, stirred to dissolve at 40-45°C, filtered sequentially with 0.8 µm and 0.45 µm microporous filter membranes, and dispensed, to obtain the final product.

[0049] The pH of the obtained liquid is 5.61, and the relative density is 1.036.

[0050] Ectoine is a typical component in the liquid composition of the present application. The inventors have found in some research experiments that the prescribed amount of edetate disodium has an adverse effect on the stability of ectoine, causing loss of ectoine in the liquid composition. Based on this problem, the inventors have unexpectedly found that the addition of an appropriate amount of threonine and sodium bisulfite in the solution can avoid the above loss of ectoine. Part of the test for this conclusion is carried out as follows.

[0051] Solution a: 10.53 mg of ectoine is accurately weighed into a 100 ml volumetric flask, dissolved in water and diluted to volume (theoretical concentration is 105.3 µg / ml, the same below), Solution b: 30.25 mg of edetate disodium and 10.26 mg of ectoine are accurately weighed into a 100 ml volumetric flask, dissolved in water and diluted to volume, Solution c: 30.36 mg of edetate disodium, 10.31 mg of ectoine, and 202.14 mg of threonine are accurately weighed into a 100 ml volumetric flask, dissolved in water and diluted to volume, Solution d: precisely weigh disodium edetate 29.72 mg, ecdysterone 10.38 mg, sodium bisulfite 75.14 mg, put into a 100 ml volumetric flask, dissolve and dilute to volume with water to prepare, Solution e: precisely weigh disodium edetate 30.13 mg, ecdysterone 10.43 mg, threonine 200.76 mg, sodium bisulfite 75.38 mg, put into a 100 ml volumetric flask, dissolve and dilute to volume with water to prepare; The eye care serum of Example 1 and the five solutions a to e are sealed in ampoules, heat treated in a 70°C water bath for 24 h, and the content of ecdysterone in the five solutions before and after heat treatment is determined using

HPLC method a

[0052] In some supplementary tests, according to the proportion of disodium edetate 30 mg, ecdysterone 10 mg and water 100 ml, all combinations of adding threonine 150 mg or 250 mg and sodium bisulfite 50 mg or 100 mg can obtain an ecdysterone residual rate of more than 98.3%, indicating that adding 0.15-0.25% threonine and 0.05-0.5% sodium bisulfite in a solution containing 0.03% disodium edetate and 0.01% ecdysterone can stabilize ecdysterone in an aqueous solution containing disodium edetate. Typically, the HPLC chart of solution a heat treated is shown in Figure 2 , and the HPLC chart of the eye care serum of Example 1 heat treated is shown in Figure 3 .

[0053]

HPLC method a

[0054] Example 2: Preparation of a liquid composition for ophthalmic use The present example provides an eye liquid composition, which can be called an eye care liquid or eye care serum, the prescription of which is (without disodium edetate): glycerin 6 g, p-hydroxyacetophenone 0.3 g, sodium hyaluronate 0.05 g, propylene glycol 6 g, menthyl glycol 0.02 g, borneol 0.02 g, methyl diisopropyl propionamide 0.3 g, menthol 0.02 g, SOLUBILISANT LRI 0.25 g, lock water magnetite 0.5 g, gentian root extract 0.2 g, maclurin 0.05 g, sodium citrate 0.0118 g, ekdoin 0.01 g, ergothioneine 0.005 g, hydrolyzed red algae extract 0.005 g, water q.s. to 100 g.

[0055] Method of preparation: 1) Half of the prescription amount of glycerin and p-hydroxyacetophenone were heated in a water bath to completely dissolve, as pre-prepared liquid A, ready for use; 2) The sodium hyaluronate, 10 times its weight of water, and the remaining amount of glycerin were pre-dispersed as pre-prepared liquid B, ready for use; 3) Stir propylene glycol, menthol and borneol uniformly, heat to 60-70°C to dissolve the material, then cool to room temperature, add methyl diisopropyl propionamide and menthol, stir to dissolve, then add SOLUBILISANT LRI, stir uniformly, as pre-prepared solution C; 4) Put the appropriate amount (about 60% of the prescription amount) of water in the liquid preparation kettle, add pre-prepared solution B under stirring, then heat to 85°C under stirring, continue to keep warm and stir for 30 min, cool to 40°C, add pre-prepared solution A under stirring, stir uniformly; 5) Add pre-prepared solution C, water-locked magnetite, gentian root extract, peonidin, sodium citrate, ectoine, ergothioneine, hydrolyzed red algae extract, the remaining water to the liquid material obtained in the previous step in turn, dissolve under stirring at a temperature of 40-45°C, filter with 0.8 µm and 0.45 µm microporous filter membranes in turn, and then dispense, to obtain the product.

[0056] Example 3: Preparation of a liquid composition for ophthalmic use The present embodiment provides an eye liquid composition which can be called eye care liquid or eye care serum, the prescription of which is (homoserine): Glycerin 6g, 4-Hydroxyacetophenone 0.3g, Sodium hyaluronate 0.05g, Propylene glycol 6g, Menthol 0.02g, Borneol 0.02g, Methyl diisopropyl propionamide 0.3g, Menthol 0.02g, SOLUBILISANT LRI 0.25g, Disodium edetate 0.03g, Water-locked magnetite 0.5g, Gentian root extract 0.2g, Peonidin 0.05g, Sodium citrate 0.0118g, Ectoine 0.01g, Homoserine 0.2g, Ergothioneine 0.005g, Hydrolyzed red algae extract 0.005g, Water q.s. to 100g.

[0057] Preparation method: 1) Half of the prescription amount of glycerin and 4-hydroxyacetophenone are heated in a water bath to dissolve completely, as pre-prepared solution A, for standby; 2) Pre-disperse sodium hyaluronate, 10 times its weight of water, and the remaining glycerin, as pre-prepared solution B, for standby; 3) Stir propylene glycol, menthol and borneol uniformly, heat to 60-70°C to dissolve the material, then cool to room temperature, add methyl diisopropyl propionamide and menthol, stir to dissolve, then add SOLUBILISANT LRI, stir uniformly, as pre-prepared liquid C; 4) Put the appropriate amount (about 60% of the prescription amount) of water and disodium edetate in a liquid preparation kettle, stir to dissolve, add pre-prepared liquid B under stirring, then heat to 85°C under stirring, continue to keep warm and stir for 30 min, cool to 40°C, add pre-prepared liquid A under stirring, stir uniformly; 5) Add pre-prepared liquid C, magnetite, gentian root extract, amentoflavone, sodium citrate, ectoine, threonine, ergothioneine, hydrolyzed red algae extract, the remaining water to the liquid material obtained in the previous step in sequence, stir to dissolve at a temperature of 40-45°C, filter with 0.8 μm and 0.45 μm microporous filter membranes in sequence, and then dispense, to obtain the product.

[0058] Example 4: Preparation of a liquid composition for ophthalmic use The present embodiment provides an eye care liquid or eye care serum, the prescription of which is as follows (with sodium bisulfite): Glycerin 6g, 4-Hydroxyacetophenone 0.3g, Sodium hyaluronate 0.05g, Propylene glycol 6g, Menthol 0.02g, Borneol 0.02g, Methyl diisopropyl propionamide 0.3g, Menthol 0.02g, SOLUBILISANT LRI 0.25g, Disodium edetate 0.03g, Magnetite 0.5g, Gentian root extract 0.2g, Amentoflavone 0.05g, Sodium citrate 0.0118g, Ectoine 0.01g, Sodium bisulfite 0.075g, Ergothioneine 0.005g, Hydrolyzed red algae extract 0.005g, Water q.s. to 100g.

[0059] Preparation method: 1) Half of the prescription amount of glycerin and 4-hydroxyacetophenone are heated in a water bath to dissolve completely, as pre-prepared liquid A, for standby use; 2) Pre-disperse sodium hyaluronate, 10 times its weight of water, the balance glycerol as pre-preparation B, ready for use; 3) Stir propylene glycol, menthyl glycol and borneol uniformly, heat to 60-70°C to dissolve the material, then cool to room temperature, add methyl diisopropyl propionamide and menthol, stir to dissolve, then add SOLUBILISANT LRI, stir uniformly, as pre-preparation C; 4) Place an appropriate amount of water (about 60% of the prescription amount) and disodium edetate in a preparation kettle, stir to dissolve, then add pre-preparation B with stirring, then heat to 85°C with stirring, continue to maintain the temperature and stir for 30 min, cool to 40°C, add pre-preparation A with stirring, stir uniformly; 5) To the liquid obtained in the previous step, add pre-preparation C, magnetite, gentian root extract, peonyl, sodium citrate, ectoine, sodium bisulfite, ergothioneine, hydrolyzed red algae extract, the balance water in sequence, stir to dissolve at a temperature of 40-45°C, filter in sequence with 0.8 µm and 0.45 µm microporous filter membranes, dispense, and it is obtained.

[0060] Example 5: Preparation of a liquid composition for ophthalmic use The present example provides an eye liquid composition which can be called eye care liquid or eye care serum, the prescription of which is (threonine and sodium bisulfite): Glycerol 6 g, p-Hydroxyacetophenone 0.3 g, Sodium hyaluronate 0.05 g, Propylene glycol 6 g, Menthyl glycol 0.02 g, Borneol 0.02 g, Methyl diisopropyl propionamide 0.3 g, Menthol 0.02 g, SOLUBILISANT LRI 0.25 g, Disodium edetate 0.03 g, Magnetite 0.5 g, Gentian root extract 0.2 g, Peonyl 0.05 g, Sodium citrate 0.0118 g, Ectoine 0.01 g, Threonine 0.2 g, Sodium bisulfite 0.075 g, Ergothioneine 0.005 g, Hydrolyzed red algae extract 0.005 g, Water to 100 g.

[0061] Method of preparation: 1) Half of the prescribed amount of glycerin and p-hydroxyacetophenone are dissolved completely in a water bath, and used as pre-prepared solution A; 2) Sodium hyaluronate, 10 times its weight of water, and the rest of glycerin are pre-dispersed, and used as pre-prepared solution B; 3) Propylene glycol, menthyl glycol, and borneol are stirred uniformly, heated to 60-70°C to dissolve the materials, then cooled to room temperature, methyl diisopropylpropionamide and menthol are added, stirred to dissolve, then SOLUBILISANT LRI is added and stirred uniformly, used as pre-prepared solution C; 4) An appropriate amount (about 60% of the prescribed amount) of water and disodium edetate are placed in a solution preparation kettle, stirred to dissolve, pre-prepared solution B is added with stirring, then heated to 85°C with stirring, continues to be stirred for 30 min at 85°C, then cooled to 40°C, pre-prepared solution A is added with stirring, and stirred uniformly; 5) Pre-prepared solution C, water-retaining magnetite, gentian root extract, peonidin, sodium citrate, ectoine, threonine, sodium bisulfite, ergothioneine, hydrolyzed red algae extract, and the rest of water are sequentially added to the solution obtained in the previous step, stirred to dissolve at 40-45°C, filtered sequentially with 0.8 µm and 0.45 µm microporous filter membranes, and then dispensed, to obtain the product.

[0062] Example 6: Preparation of a liquid composition for ophthalmic use The present example provides an eye liquid composition, which can be referred to as an eye care liquid or eye care serum, with the following prescription: glycerin 5.4 g, p-hydroxyacetophenone 0.33 g, sodium hyaluronate 0.045 g, propylene glycol 6.6 g, menthyl glycol 0.018 g, borneol 0.022 g, methyl diisopropylpropionamide 0.27 g, menthol 0.022 g, SOLUBILISANT LRI 0.275 g, disodium edetate 0.027 g, water-retaining magnetite 0.55 g, gentian root extract 0.18 g, peonidin 0.055 g, sodium citrate 0.0106 g, ectoine 0.011 g, threonine 0.18 g, sodium bisulfite 0.0825 g, ergothioneine 0.0045 g, hydrolyzed red algae extract 0.0055 g, Water q.s. 100 g.

[0063] Method of preparation: 1) Half of the prescribed amount of glycerin and p-hydroxyacetophenone are heated in a water bath until completely dissolved, as pre-prepared solution A, ready for use; 2) Sodium hyaluronate, 10 times its weight of water, the rest of the glycerin are pre-dispersed as pre-prepared solution B, ready for use; 3) Propylene glycol, menthyl glycol and borneol are stirred until uniform, heated to 60-70°C until the material is dissolved, then cooled to room temperature, add methyl diisopropyl propionamide and menthol, stir until dissolved, then add SOLUBILISANT LRI, stir until uniform, as pre-prepared solution C; 4) The appropriate amount of water (about 60% of the prescribed amount) is placed in a liquid preparation kettle with disodium edetate, stirred until dissolved, then pre-prepared solution B is added with stirring, then heated to 85°C with stirring, continue to maintain the temperature and stir for 30 min, then cool to 40°C, add pre-prepared solution A with stirring, stir until uniform; 5) To the liquid obtained in the previous step, add pre-prepared solution C, water-locked magnetite, gentian root extract, peony aldehyde, sodium citrate, ectoine, threonine, sodium bisulfite, ergothioneine, hydrolyzed red algae extract, the rest of the water, stir until dissolved at a temperature of 40-45°C, filter with 0.8 µm and 0.45 µm microporous filter membranes in turn, then dispense, and it is obtained.

[0064] Example 7: Preparation of a liquid composition for ophthalmic use The present example provides an eye care liquid composition, which can be called eye care liquid or eye care serum, with the following prescription: Glycerin 6.6 g, p-hydroxyacetophenone 0.27 g, Sodium hyaluronate 0.055 g, Propylene glycol 5.4 g, Menthyl glycol 0.022 g, Borneol 0.018 g, Methyl diisopropyl propionamide 0.33 g, Menthol 0.018 g, SOLUBILISANT LRI 0.225 g, Disodium edetate 0.033 g, Water-locked magnetite 0.45 g, Gentian root extract 0.22 g, Peony aldehyde 0.045 g, Sodium citrate 0.013 g, Ectoine 0.009 g, Threonine 0.22 g, Sodium bisulfite 0.0675 g, Ergothioneine 0.0055 g, Hydrolyzed red algae extract 0.0045 g, Water q.s. to 100 g.

[0065] Preparation: 1) Half of the prescribed amount of glycerin and p-hydroxyacetophenone were heated in a water bath to complete dissolution, as pre-prepared solution A, ready for use; 2) Sodium hyaluronate, 10 times its weight of water, and the rest of the glycerin were pre-dispersed as pre-prepared solution B, ready for use; 3) Propylene glycol, menthyl glycol, and borneol were stirred to homogeneity, heated to 60-70°C to dissolve the materials, then cooled to room temperature, methyl diisopropylpropionamide and menthol were added, stirred to dissolve, then SOLUBILISANT LRI was added, stirred to homogeneity, as pre-prepared solution C; 4) An appropriate amount (about 60% of the prescribed amount) of water was placed in a liquid preparation kettle with edetate disodium, stirred to dissolve, pre-prepared solution B was added with stirring, then heated to 85°C with stirring, continued to maintain the temperature and stir for 30 min, cooled to 40°C, pre-prepared solution A was added with stirring, stirred to homogeneity; 5) Pre-prepared solution C, lock water magnetite, gentian root extract, methoxylated resorcinol, sodium citrate, ectoine, threonine, sodium bisulfite, ergothioneine, hydrolyzed red algae extract, and the rest of the water were added in sequence to the liquid obtained in the previous step, stirred to dissolve at a temperature of 40-45°C, filtered in sequence with 0.8 µm and 0.45 µm microporous filter membranes, dispensed, and it was done.

[0066] In addition, the liquid compositions obtained in Examples 2-7 were treated according to the method of 70°C heat treatment for 24 h described above, and the content of ectoine in the 6 solutions was determined before and after heat treatment according to the HPLC method a, and the residual rate (%) of ectoine in the solution after 24 h of heat treatment was calculated for each solution. The results were: the residual rate of the eye care serum of Example 2 was 99.1%, the residual rate of the eye care serum of Example 3 was 91.3%, the residual rate of the eye care serum of Example 4 was 92.9%, the residual rate of the eye care serum of Example 5 was 99.3%, the residual rate of the eye care serum of Example 6 was 99.0%, and the residual rate of the eye care serum of Example 7 was 99.2%. These results were basically consistent with the results obtained in solutions a-e above. Typically, the HPLC chart of the eye care serum of Example 5 after heat treatment is shown in Figure 4 .

[0067] The pH values of the liquid compositions obtained in Examples 2-7 were all in the range of 5.0-6.0, for example the pH value of the liquid composition obtained in Example 5 was 5.52, and the relative densities of the liquid compositions obtained in Examples 2-7 were all in the range of 1.01-1.05, for example the relative density of the liquid composition obtained in Example 5 was 1.027.

[0068] Example 8: Quality investigation of the liquid composition In this embodiment, the seven liquid compositions obtained in Examples 1-7 were detected for mercury, lead, arsenic, cadmium, dioxane, pH value (25°C) according to the method of “Cosmetic Safety Technology Standard (2015 Edition)”, all samples met the standard limit value provisions, for example, the results of Example 7 liquid composition detected by Huachu Testing Company are shown in Table 6. Figure 5 .

[0069] In this embodiment, the seven liquid compositions obtained in Examples 1-7 were detected for mercury, lead, arsenic, cadmium, dioxane, pH value (25°C) according to the method of “Cosmetic Safety Technology Standard (2015 Edition)”, all samples met the standard limit value provisions, for example, the results of Example 7 liquid composition detected by Huachu Testing Company are shown in Table 6. Figure 5 .

[0070] In this embodiment, according to “QB / T 2660-2004 <Cosmetic Water>”, “Cosmetic Safety Technology Standard (2015 Edition)”, “GB / T13531.4-2013 <General Test Methods for Cosmetics Determination of Relative Density>”, the seven liquid compositions obtained in Examples 1-7 were detected for cold resistance, heat resistance, appearance, aroma, pH, etc. 15 items, all samples met the standard limit value provisions, for example, the results of Example 6 liquid composition detected by Huachu Testing Company are shown in Table 7. Figure 6 .

[0071] In addition, in this embodiment, the diethylene glycol in the seven liquid compositions obtained in Examples 1-7 was also determined according to “QB / T 5411-2019 <Determination of Prohibited Substance Diethylene Glycol in Cosmetics by Gas Chromatography>”, the limit value specified by the national standard should be <400mg / kg, the measured results of diethylene glycol in the seven liquid compositions were all not detected.

[0072] The present application uses the materials in the formulations listed in Examples 1-7 to produce liquid compositions for eye use with excellent performance, which can effectively relieve eye strain. The basic liquid composition produced by the method of the present application shows excellent biological effect, and a typical product is an eye care serum product approved by the relevant regulatory authorities and allowed to be sold with the code Guangdong G Cosmetics Network Preparation 2023423624. Such products show excellent effect in relieving eye fatigue through external and periorbital use on human eyes; for example, 38 volunteers (23 women and 15 men, aged 26-35) who frequently use electronic screens and are often troubled by eye strain use the eye care serum, apply about 0.2 ml to the outer eye (within 2 cm of the outer periphery of the upper and lower eyelids) and gently rub for 10 seconds at 8:00-9:00, 11:00-12:00, 14:00-15:00, and 19:00-20:00 every day, and continuously use for 2 weeks. During this period, electronic screens are used at the usual frequency, and the eye care serum is used. After 2 days of use, 34 subjects (21 women and 13 men) felt that eye strain could be significantly relieved.

[0073] The present application illustrates the detailed method of the present application through the above examples, but the present application is not limited to the above detailed method, that is, it does not mean that the present application must rely on the above detailed method to be implemented. It should be understood by those skilled in the art that any improvement on the present application, equivalent replacement of each raw material of the product of the present application, addition of auxiliary ingredients, selection of specific methods, etc. fall within the protection scope and disclosure scope of the present application.

Claims

1. A liquid composition for eye use, comprising the following components in the indicated weight proportions: glycerin 5.4g~6.6g, p-hydroxyacetophenone 0.27g~0.33g, sodium hyaluronate 0.045g~0.055g, propylene glycol 5.4g~6.6g, menthol 0.018g~0.022g, borneol 0.018g~0.022g, methyl diisopropyl propionamide 0.27g~0.33g, menthol 0.018g~0.022g, solubilisant 10g (LRI) 0.225g~0.275g, disodium edetate 0.027g~0.033g, hydrophilic magnetite 0.45g~0.55g, gentian root extract 0.18g~0.22g, and tau phenol 0.045g. ~0.055g, sodium citrate 0.0106g~0.013g, ectoine 0.009g~0.011g, ergothioneine 0.0045g~0.0055g, hydrolyzed red algae extract 0.0045g~0.0055g, water as needed to 100g.

2. The liquid composition according to claim 1, which is prepared using a method comprising the steps of: 1) Dissolve half the amount of glycerin and p-hydroxyacetophenone in a water bath until completely dissolved, and use this as pre-prepared solution A for later use; 2) Pre-disperse sodium hyaluronate, 10 times its weight of water, and the remainder glycerin to prepare pre-solution B for later use; 3) Stir propylene glycol, menthol and borneol evenly, heat to 60℃-70℃ to dissolve the materials, then cool to room temperature, add methyl diisopropyl propionamide and menthol, stir to dissolve, then add SOLUBILISANT LRI, stir evenly, and use as pre-prepared liquid C. 4) Place an appropriate amount of water and disodium edetate in a mixing pot, stir to dissolve, add pre-prepared solution B while stirring, then heat to 85°C while stirring, continue to keep warm and stir for 30 minutes, cool down to 40°C, add pre-prepared solution A while stirring, and stir evenly. 5) Add pre-prepared liquid C, water-locking magnet, gentian root extract, tau phenol, sodium citrate, ectoine, ergothioneine, hydrolyzed red algae extract, and the remaining water to the liquid obtained in the previous step in sequence. Stir at 40℃-45℃ to dissolve, filter sequentially through 0.8µm and 0.45µm microporous membranes, and dispense to obtain the final product. For example, the liquid composition may also include threonine and / or sodium bisulfite; for example, it may also include 0.18g~0.22g of threonine and / or 0.0675g~0.0825g of sodium bisulfite; for example, the threonine and / or sodium bisulfite may be added together with ectoine.

3. The liquid composition according to claim 1, comprising the following components in the indicated weight proportions: 6g glycerin, 0.3g p-hydroxyacetophenone, 0.05g sodium hyaluronate, 6g propylene glycol, 0.02g menthol, 0.02g borneol, 0.3g methyl diisopropylpropionamide, 0.02g menthol, 0.25g SOLUBILISANT LRI, 0.03g disodium edetate, 0.5g hydromagnetite, 0.2g gentian root extract, 0.05g tau phenol, 0.0118g sodium citrate, 0.01g ectoine, 0.2g threonine, 0.075g sodium bisulfite, 0.005g ergothioneine, 0.005g hydrolyzed red algae extract, and water to a total weight of 100g.

4. The liquid composition according to claim 1, comprising the following components in the indicated weight proportions: 5.4 g glycerin, 0.33 g p-hydroxyacetophenone, 0.045 g sodium hyaluronate, 6.6 g propylene glycol, 0.018 g menthol, 0.022 g borneol, 0.27 g methyl diisopropyl propionamide, 0.022 g menthol, 0.275 g SOLUBILISANT LRI, 0.027 g disodium edetate, 0.55 g magnetite, 0.18 g gentian root extract, 0.055 g tsaokool, 0.0106 g sodium citrate, 0.011 g ectoine, 0.18 g threonine, 0.0825 g sodium bisulfite, 0.0045 g ergothioneine, 0.0055 g hydrolyzed red algae extract, and water to a total weight of 100 g.

5. The liquid composition according to claim 1, comprising the following components in the indicated weight proportions: 6.6 g glycerin, 0.27 g p-hydroxyacetophenone, 0.055 g sodium hyaluronate, 5.4 g propylene glycol, 0.022 g menthol, 0.018 g borneol, 0.33 g methyl diisopropylpropionamide, 0.018 g menthol, 0.225 g SOLUBILISANT LRI, 0.033 g disodium edetate, 0.45 g hydromagnetite, 0.22 g gentian root extract, 0.045 g tsaokool, 0.013 g sodium citrate, 0.009 g ectoine, 0.22 g threonine, 0.0675 g sodium bisulfite, 0.0055 g ergothioneine, 0.0045 g hydrolyzed red algae extract, and water to a total weight of 100 g.

6. Use of a liquid composition in the preparation of a product for relieving eye strain, said liquid composition comprising the following components in the indicated weight proportions: 5.4g-6.6g glycerin, 0.27g-0.33g p-hydroxyacetophenone, 0.045g-0.055g sodium hyaluronate, 5.4g-6.6g propylene glycol, 0.018g-0.022g menthol, 0.018g-0.022g borneol, 0.27g-0.33g methyl diisopropyl propionamide, 0.018g-0.022g menthol, 0.225g-0.275g SOLUBILISANT LRI, 0.027g-0.033g disodium edetate, 0.45g-0.55g magnetite, 0.18g-0.22g gentian root extract, and 0.045g tau phenol. ~0.055g, sodium citrate 0.0106g~0.013g, ectoine 0.009g~0.011g, ergothioneine 0.0045g~0.0055g, hydrolyzed red algae extract 0.0045g~0.0055g, water as needed to 100g.

7. The use according to claim 6, wherein the liquid composition is prepared using a method comprising the steps of: 1) Dissolve half the amount of glycerin and p-hydroxyacetophenone in a water bath until completely dissolved, and use this as pre-prepared solution A for later use; 2) Pre-disperse sodium hyaluronate, 10 times its weight of water, and the remainder glycerin to prepare pre-solution B for later use; 3) Stir propylene glycol, menthol and borneol evenly, heat to 60℃-70℃ to dissolve the materials, then cool to room temperature, add methyl diisopropyl propionamide and menthol, stir to dissolve, then add SOLUBILISANT LRI, stir evenly, and use as pre-prepared liquid C. 4) Place an appropriate amount (about 60% of the prescription amount) of water and disodium edetate in a mixing pot, stir to dissolve, add pre-prepared solution B while stirring, then heat to 85°C while stirring, continue to keep warm and stir for 30 minutes, cool down to 40°C, add pre-prepared solution A while stirring, and stir evenly. 5) Add pre-prepared liquid C, water-locking magnet, gentian root extract, tau phenol, sodium citrate, ectoine, ergothioneine, hydrolyzed red algae extract, and the remaining water to the liquid obtained in the previous step in sequence. Stir at 40℃-45℃ to dissolve, filter sequentially through 0.8µm and 0.45µm microporous membranes, and dispense to obtain the final product. For example, the liquid composition may also include threonine and / or sodium bisulfite; for example, it may also include 0.18g~0.22g of threonine and / or 0.0675g~0.0825g of sodium bisulfite; for example, the threonine and / or sodium bisulfite may be added together with ectoine.

8. The use according to claim 6, wherein the liquid composition comprises the following components in the indicated weight proportions: 6g glycerin, 0.3g p-hydroxyacetophenone, 0.05g sodium hyaluronate, 6g propylene glycol, 0.02g menthol, 0.02g borneol, 0.3g methyl diisopropylpropionamide, 0.02g menthol, 0.25g SOLUBILISANT LRI, 0.03g disodium edetate, 0.5g hydromagnetite, 0.2g gentian root extract, 0.05g tau phenol, 0.0118g sodium citrate, 0.01g ectoine, 0.2g threonine, 0.075g sodium bisulfite, 0.005g ergothioneine, 0.005g hydrolyzed red algae extract, and water to a total weight of 100g.

9. The use according to claim 6, wherein the liquid composition comprises the following components in the indicated weight proportions: 5.4 g glycerin, 0.33 g p-hydroxyacetophenone, 0.045 g sodium hyaluronate, 6.6 g propylene glycol, 0.018 g menthol, 0.022 g borneol, 0.27 g methyl diisopropylpropionamide, 0.022 g menthol, 0.275 g SOLUBILISANT LRI, 0.027 g disodium edetate, 0.55 g hydromagnetite, 0.18 g gentian root extract, 0.055 g tsaokool, 0.0106 g sodium citrate, 0.011 g ectoine, 0.18 g threonine, 0.0825 g sodium bisulfite, 0.0045 g ergothioneine, 0.0055 g hydrolyzed red algae extract, and water to a total weight of 100 g.

10. The use according to claim 6, wherein the liquid composition comprises the following components in the indicated weight proportions: 6.6 g glycerin, 0.27 g p-hydroxyacetophenone, 0.055 g sodium hyaluronate, 5.4 g propylene glycol, 0.022 g menthol, 0.018 g borneol, 0.33 g methyl diisopropylpropionamide, 0.018 g menthol, 0.225 g SOLUBILISANT LRI, 0.033 g disodium edetate, 0.45 g hydromagnetite, 0.22 g gentian root extract, 0.045 g tsaourol, 0.013 g sodium citrate, 0.009 g ectoine, 0.22 g threonine, 0.0675 g sodium bisulfite, 0.0055 g ergothioneine, 0.0045 g hydrolyzed red algae extract, and water to a total weight of 100 g.

Images